CLINICAL OUTCOMES OF COMBINED SIROLIMUS AND PACLITAXEL-BASED ENDOVASCULAR THERAPY IN PATIENTS WITH DIABETIC FOOT ULCERS AND CHRONIC LIMB-THREATENING ISCHEMIA FOLLOWING ANGIOPLASTY : A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES
The International Journal of Medical Science and Health Research · 19.11.2026 · 49 (3) · 712-805
DOI: 10.70070/w3w8ka29 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The International Journal of Medical Science and Health Research, online erschienen am 19.11.2026. Verfasst von I Gede Ryan Widhi Wirajaya und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetisches Fußsyndrom
Abstract (Originalsprache)
Introduction
Diabetic foot ulcer (DFU) complicated by chronic limb-threatening ischemia (CLTI) is driven by diffuse, calcified infrapopliteal disease in which plain old balloon angioplasty (POBA) is limited by early restenosis. Paclitaxel-based devices (cytotoxic microtubule stabilisation) and sirolimus-based devices (cytostatic mTOR inhibition) were developed to prevent neointimal hyperplasia, yet no synthesis has integrated both drug platforms—individually, head-to-head, or as complementary (combined) strategies—in diabetic/CLTI populations. We aimed to quantify the clinical outcomes of sirolimus- and paclitaxel-based endovascular therapy after angioplasty in patients with DFU and CLTI.
Methods
The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. Eligible designs were randomised controlled trials (RCTs), prospective/retrospective cohort, case–control, cross-sectional and single-arm observational studies enrolling adults with DFU and/or CLTI (enrichment threshold ≥40% CLTI or ≥40% diabetes) treated with sirolimus-eluting stents/balloons (SES/SCB) and/or paclitaxel-coated balloons/eluting stents (PCB/PES) after angioplasty. Systematic reviews were excluded from synthesis and used only in the Discussion. Risk of bias was assessed with RoB 2, ROBINS-I and MINORS. Random-effects (DerSimonian–Laird) risk ratios (RR), mean differences and logit-transformed proportions were pooled; heterogeneity (I², τ², 95% prediction interval), subgroup (drug class), leave-one-out, cumulative, meta-regression and small-study (Egger, Begg) analyses were performed and certainty was graded with GRADE.
Results
Thirty-five studies (47 reports) were included: 20 RCTs, 4 non-randomised comparative studies and 11 single-arm cohorts. Compared with non-drug angioplasty/stenting, drug-eluting therapy reduced loss of primary patency (9 RCTs, n = 1204; RR 0.60, 95% CI 0.43–0.82; I² = 78%; number needed to treat ≈ 6), with consistent effects for paclitaxel (RR 0.63, 0.43–0.93) and sirolimus (RR 0.50, 0.35–0.70; P-interaction = 0.37), and reduced clinically driven target lesion revascularisation (7 RCTs, n = 998; RR 0.45, 0.33–0.62; I² = 0%; NNT ≈ 9). Late lumen loss was lower with paclitaxel-coated balloons (MD −0.44 mm, −0.84 to −0.05). Major amputation (RR 0.67, 0.27–1.70) and all-cause mortality (RR 0.90, 0.72–1.12) were not significantly different; the composite major adverse limb event was reduced by sirolimus (SirPAD; RR 0.59, 0.43–0.80) but not by paclitaxel (RR 1.19, 0.75–1.89; P-interaction = 0.012). In head-to-head diabetic/CLTI comparisons, sirolimus-family devices reduced loss of patency versus paclitaxel (RR 0.53, 0.29–0.96) without differences in amputation or mortality. Pooled single-arm cohorts and trial arms showed 6-month patency of 77.1% with sirolimus-coated balloons vs 67.8% with paclitaxel-coated balloons, and wound healing of 81.4% vs 79.7%. No small-study effects were detected. Certainty ranged from moderate (revascularisation) to very low (amputation, head-to-head).
Discussion
Both antiproliferative platforms convert angiographic benefit into fewer repeat revascularisations in diabetic CLTI, but neither has yet been proven to reduce limb loss or death. Sirolimus offers a wider therapeutic window, no slow-flow phenomenon and the only randomised reduction in major adverse limb events, whereas paclitaxel carries the longest efficacy record but persistent early-amputation and late-mortality uncertainty. Mechanistic complementarity (G1 versus G2/M arrest; carrier-dependent versus lipophilic retention) supports segment-tailored and bail-out combined use and justifies dual-drug platforms, which remain pre-clinical.
Conclusion
In patients with DFU and CLTI undergoing angioplasty, sirolimus- and paclitaxel-based endovascular therapies roughly halve clinically driven revascularisation and reduce restenosis without increasing mortality, with sirolimus showing a more favourable limb-event and safety profile. Adequately powered infrapopliteal RCTs with wound-healing and limb-salvage endpoints, and trials of deliberate sequential or dual-drug strategies, are required.
Zitieren
APA
Wirajaya, I. G. R. W., & Putra, P. G. W. (2026). CLINICAL OUTCOMES OF COMBINED SIROLIMUS AND PACLITAXEL-BASED ENDOVASCULAR THERAPY IN PATIENTS WITH DIABETIC FOOT ULCERS AND CHRONIC LIMB-THREATENING ISCHEMIA FOLLOWING ANGIOPLASTY : A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES. The International Journal of Medical Science and Health Research, 49(3), 712-805. https://doi.org/10.70070/w3w8ka29
Vancouver
Wirajaya IGRW, Putra PGW. CLINICAL OUTCOMES OF COMBINED SIROLIMUS AND PACLITAXEL-BASED ENDOVASCULAR THERAPY IN PATIENTS WITH DIABETIC FOOT ULCERS AND CHRONIC LIMB-THREATENING ISCHEMIA FOLLOWING ANGIOPLASTY : A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES. The International Journal of Medical Science and Health Research. 2026;49(3):712-805. doi:10.70070/w3w8ka29
BibTeX
@article{Wirajaya2026,
author = {Wirajaya, I Gede Ryan Widhi and Putra, Putu Gede Wirakusuma},
title = {CLINICAL OUTCOMES OF COMBINED SIROLIMUS AND PACLITAXEL-BASED ENDOVASCULAR THERAPY IN PATIENTS WITH DIABETIC FOOT ULCERS AND CHRONIC LIMB-THREATENING ISCHEMIA FOLLOWING ANGIOPLASTY : A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES},
journal = {The International Journal of Medical Science and Health Research},
year = {2026},
volume = {49},
number = {3},
pages = {712--805},
doi = {10.70070/w3w8ka29}
}
EUVIMED